GlassScriptPhysician profile
Robert G Drake
NPI 1528151685
$9,945.14
in general payments reported to CMS, 2019-2025
39 companies · $797 in 2025
The $797 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,469 · 2020: $1,738 · 2021: $1,642 · 2022: $1,124 · 2023: $1,029 · 2024: $1,146 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,972.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,876.63 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,541.89 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $1,422.89 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $674.98 | 2019-2025 | Airsupra, Breztri |
| Amarin Pharma, INC. | $669.34 | 2019-2023 | |
| Amgen INC. | $569.89 | 2019-2025 | Otezla, Repatha, Evenity |
| Sunovion Pharmaceuticals INC. | $489.00 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $484.57 | 2019-2024 | Capvaxive |
| Janssen Pharmaceuticals, INC | $290.19 | 2019-2022 | |
| Intuitive Surgical, INC. | $270.02 | 2024-2025 | |
| Abbvie INC. | $237.46 | 2021-2025 | Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $180.28 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.20 | 2021-2025 | Xifaxan |
| Horizon Therapeutics Plc | $153.64 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.87 | 2021-2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $101.97 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Inspire Medical Systems, INC. | $100.00 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $82.16 | 2020-2024 | Camzyos |
| Teva Pharmaceuticals USA, INC. | $71.32 | 2022-2023 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $37.72 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $36.32 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.15 | 2024-2025 | Caplyta |
| Lundbeck LLC | $34.38 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $32.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $29.88 | 2022 | |
| Abbott Laboratories | $29.71 | 2024-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $24.02 | 2023 | Gemtesa |
| Stryker Corporation | $20.77 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Xeris Pharmaceuticals, INC. | $19.48 | 2022 | |
| Esperion Therapeutics, INC. | $16.90 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.63 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.47 | 2023 | Quviviq |
| Csl Behring | $13.59 | 2024 | Haegarda |
| Allergan, INC. | $13.02 | 2020 | |
| Metacel Pharmaceuticals LLC | $12.95 | 2022 | |
| Eisai INC. | $12.76 | 2021 | |
| Genentech USA, INC. | $12.59 | 2019 | |
| Astellas Pharma US INC | $12.12 | 2022 | |
| Mylan Specialty L.P. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Drake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.